Drug rash with eosinophilia and systemic symptoms syndrome induced by sulfasalazine.
Bahat
Gulistan
G
Celik
Hulya Gamze
HG
Tufan
Fatih
F
Saka
Bulent
B
D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002443:Ceftriaxone / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004802:Eosinophilia / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use; D013407:Sulbactam / Q000627:therapeutic use; D012460:Sulfasalazine / Q000009:adverse effects*; D013577:Syndrome
D000900:Anti-Bacterial Agents; D018501:Antirheumatic Agents; D012460:Sulfasalazine; D002443:Ceftriaxone; D000667:Ampicillin; D013407:Sulbactam; D008775:Methylprednisolone